盘后交易 19:45 (美东)3.060USD+0.015+0.49%关键数据
3.180今开
3.425最高
354.42K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.18%换手率
3.190昨收
2.985最低
1.09M成交额
亏损市盈率静
1.25市净率
0.00%股息率 TTM
-36.96%ROA
6.44052周最高
24.96量比
-95.06M净利润
194.47M总股本
-0.9220每股收益TTM
0.20Beta
-42.75%ROE
2.56052周最低
13.79%振幅
100.00%毛利率
591.19M总市值
1.26回报/风险
4.33%风险率

即将为您带来更多新闻,敬请期待。。。
Altimmune Inc评分
-0.07与上次评分对比预测8.36
财务诊断7.07
技术分析3.55
公司估值6.97
机构认同度3.00
风险评估5.23
分析师评级
买入评级
17.111目标均价
+436.40%涨幅空间
Altimmune Inc 最新财报电话会记录
阿尔蒂蒙 (ALT) 2026财年第二季度业绩电话会议:PERFORMA启动,现金达5.19亿美元
Altimmune 2026年第二季度业绩电话会议:PERFORMA III期临床试验启动招募,RECLAIM AUD数据支持关键性试验规划,现金储备达5.19亿美元。
财务指标
货币: USD

由于公司未披露,未能获取相关数据
货币: USD

由于公司未披露,未能获取相关数据
Altimmune Inc 简介
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
行业生物技术与医疗研究
公司代码ALT
员工数量59
国家United States of America
持股情况
| 持股股东 | 占比 |
|---|
| Deep Track Capital LP | 9.91% |
|---|
| BlackRock Institutional Trust Company, N.A. | 4.04% |
|---|
| State Street Investment Management (US) | 3.68% |
|---|
| Viking Global Investors LP | 3.45% |
|---|
| 股东类型 | 占比 |
|---|
| Investment Advisor | 18.22% |
|---|
| Hedge Fund | 14.76% |
|---|
| Investment Advisor/Hedge Fund | 11.03% |
|---|
| Venture Capital | 3.35% |
|---|
常见问题
Altimmune Inc(ALT)的当前股价是多少?
Altimmune Inc(ALT)的当前股价是 3.04。
Altimmune Inc股票的52周最高点是多少?
Altimmune Inc股票的52周最高点是6.44。
Altimmune Inc股票的52周最低点是多少?
Altimmune Inc股票的52周最低点是2.56。
Altimmune Inc的市值是591.19M。
现在Altimmune Inc(ALT)的股票是买入、持有还是卖出?
根据分析师评级,Altimmune Inc(ALT)的总体评级为买入,目标价格为17.11。
Altimmune Inc(ALT)股票的每股收益(EPS TTM)是多少
Altimmune Inc(ALT)股票的每股收益(EPS TTM)是-0.92。